RWGNYC's Blog
Sunday, October 15, 2006
globeandmail.com: Ambrilia signs HIV-AIDS drug deal with Merck
globeandmail.com: Ambrilia signs HIV-AIDS drug deal with Merck: "Drug developer Inc. is in line to receive up to $232-million (U.S.) in a licensing deal for its HIV-AIDS drug from Merck & Co.
Under the accord for its early-stage flagship PPL-100 drug, Montreal-based Ambrilia will receive an upfront payment of $17-million and up to $215-million in additional payments if the drug completes clinical testing, regulatory review and approval, and sales."
Under the accord for its early-stage flagship PPL-100 drug, Montreal-based Ambrilia will receive an upfront payment of $17-million and up to $215-million in additional payments if the drug completes clinical testing, regulatory review and approval, and sales."
:: posted by R. W. Graf, 6:20 AM
